A Swiss chemical-pharmaceutical firm that produces active ingredients and intermediate products for generic pharmaceuticals is looking to purchase the totality or majority of shares in a company producing finished pharmaceutical products (especially injectable products) to fill out its catalogue of oncological, cardiovascular and gastro-intestinal products.
Conditions of complete confidentially will apply to the assessment of any proposals received in response to this announcement.

Swiss investment company with a focus in the pharmaceutical biotechnologies sector seeks to purchase, or as a secondary option to pay into the share capital of, a company using recombinant DNA technology to produce second-generation pharmaceuticals.
Further conditions will be agreed upon subsequent to a fruitful initial contact.

European multinational corporation with a prominent position in the biomedical technologies market is pursuing an investment project in Brazil with the objective of achieving significant growth in terms of turnover. This investment project is primarily directed at acquiring companies with locally established production plants as part of a project of horizontal integration. The company is thus interested in proposals involving both consolidated and start-up businesses working in the sector of cardiovascular pathology treatment technologies, or in neighboring and/or complementary sectors.